Sectors
- Biotech
- Digital Health
- Healthcare
- Medical Technology
- Service & Technology
- Special Industrial Machinery
- Strategy
Research Coverage
- Actinium Pharmaceuticals, Inc. (ATNM)
- Energy Fuels Inc. (UUUU)
- Hyperfine, Inc. (HYPR)
- Mirion Technologies, Inc. (MIR)
- Radiopharm Theranostics Ltd. (RADX-US)
- RadNet, Inc. (RDNT)
- Tango Therapeutics, Inc. (TNGX)
- The Oncology Institute, Inc. (TOI)
Affiliations
- American Association for Cancer Research
- Society for Immunotherapy of Cancer
- American Society of Clinical Oncology
- Cancer Prevention and Research Institute of Texas
Biography
Yuan Zhi, Ph.D., is a senior healthcare equity research analyst at B. Riley Securities. He joined the healthcare research team in 2020 to focus on the coverage of smid-cap biotech companies developing cutting-edge therapeutics. His research coverage focuses on the value chain of radiopharmaceuticals and oncology care. Dr. Zhi also serves as a product development peer reviewer at the Cancer Prevention and Research Institute of Texas. Before joining B. Riley, he was with Sirona Capital, a family office focusing on biotech investment. Prior to Sirona Capital, he was trained through an R&D internship at Elanco, developing vaccines and biologics; the Regulatory Affairs Training Program at Duke University School of Medicine; and Quantitative Sciences in Drug Development at Novartis.
Dr. Zhi received a B.Sc. in chemistry from Wuhan University and a Ph.D. in biochemistry from Texas A&M University. He passed the CFA level II exam in 2018.